Pulmonary Fibrosis

Avalyn Pharma Raises $100M to Advance Inhaled Lung Disease Drugs

3 days ago talkbio0Tagged AP01, AP02, aspects of adverse effects, Avalyn, Clinical Trials, drug safety, Holdings, inhaled lung disease, nintedanib, Pharma, pirfenidone, Pulmonary Fibrosis, Series D, SNCG gene, Suvretta Capital Management

Avalyn Pharma; $100 million Series D; inhaled lung disease medications; pulmonary fibrosis; AP01; AP02; pirfenidone; nintedanib; clinical trials; drug safety; side effects; Suvretta Capital Management; SR One; Novo Holdings

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

5 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

Boehringer Ingelheim Prepares NDA Filing for Pulmonary Fibrosis Drug After Positive Phase 3 Results

10 months ago talkbio0Tagged boehringer ingelheim, Idiopathic Pulmonary Fibrosis, NDA, nerandomilast, Phase 3, Pulmonary Fibrosis

Boehringer Ingelheim, pulmonary fibrosis, NDA filing, Phase 3 data, nerandomilast, idiopathic pulmonary fibrosis (IPF)